ReShape Lifesciences® Presents Data on its Proprietary Diabetes Bloc-Stim Neuromodulation™ Device at the ASMBS 2023 Annual Meeting
June 28 2023 - 8:31AM
ReShape Lifesciences Inc. (Nasdaq:
RSLS), the premier physician-led weight loss and metabolic
health solutions company, today presented data on its proprietary
Diabetes Bloc-Stim Neuromodulation™ (DBSN™) device in an e-poster
at the American Society for Metabolic and Bariatric Surgery (ASMBS)
2023 Annual Meeting, being held in Las Vegas, NV, June 25 - 29,
2023.
“Type 2 Diabetes Mellitus (T2DM) remains
challenging to effectively treat, despite medication, surgery and
diet,” stated Jonathan Waataja, Ph.D. Director of Research at
ReShape Lifesciences. “ReShape’s DBSN™ device selectively modulates
vagal block and stimulation to the liver and pancreas to manage
blood glucose. Increased glycemic control has been demonstrated in
a Zucker rat model of T2DM as well as in an alloxan treated swine
model of T2DM. In-vivo evidence in swine suggests that multiple
applications of stimulation of the celiac branch did not cause beta
cell exhaustion using the DBSN™ device and, with further studies,
may hold significant promise to treat T2DM.”
E-Poster Details:
- Poster Title: The Insulin Response to Oral
Glucose Tolerance Tests did not Diminish Following Prolonged
Stimulation of the Vagus Nerve Celiac Branch in the Study of a
Novel Bioelectronic Treatment for Type 2 Diabetes Mellitus
- Poster Number: A223
- Author: Jonathan J. Waataja, Ph.D.
- Session: E-Posters
- Date: June 27, 2023
- Time: 9:00 am -12:30 pm PT
In swine experiments (n=3) glycemic control was
assessed by applying stimulation and block for the duration of six
4-hour oral glucose tolerance tests (OGTTs). The total cumulative
time was 24 hours which may lead to beta cell exhaustion. To test
for exhaustion blood insulin was measured during an OGTT prior to
and following experiments. The insulin response was quantified by
calculating the area under the curve (AUC) of insulin versus time
(µIU/mL*min=area unit (AU)). There was an apparent, but
non-significant, increase in baseline insulin following stimulation
and block experiments (pre-experiments =10.7±2.6 µIU/mL,
post-experiments=15.4±2.9 µIU/mL, p=0.28). In terms of overall
response there was no significant change in AUC (pre-experiments
=3906±565 AU, post-experiments=5866±698 AU, p=0.09).
“The presentation of this data at such an
important industry conference is a testament to the strength of the
pre-clinical evidence showing our proprietary DBSN™ device’s
potential to address the enormous T2DM market,” stated Paul F.
Hickey, President and Chief Executive Officer of ReShape
Lifesciences. “The DBSN™ device has the potential to deliver truly
personalized therapy by being able to adjust insulin production, as
needed, for any individual, thus potentially reducing their
dependence on medication. Given the promise of this approach, we
will continue to seek non-dilutive funding from organizations such
as the NIH, while simultaneously working with top researchers and
industry leading strategic corporate partners to potentially bring
this novel therapeutic to market.”
About Diabetes Bloc-Stim
Neuromodulation™ DeviceThe Diabetes Bloc-Stim
Neuromodulation™ (DBSN™) system is a novel therapeutic concept that
is implanted minimally invasively and delivers bio-electronic
neuromodulation of vagus nerve branches that are innervating organs
which regulate plasma glucose. The DBSN™ system stimulates vagus
celiac fibers of the pancreas to release insulin during
stimulation, while blocking the hepatic vagal branch, innervating
the liver, to decrease glucose release and decrease insulin
resistance following ligation. The DBSN™ system utilizes a
proprietary, reversable and adjustable electrical blockade felt to
be key to the future of personalized medicine. The DBSN™ system is
superior to both standalone stimulation of the vagus nerve that has
shown mixed results, and vagus nerve ligation that has undesirable
effects.
About ReShape
Lifesciences™ReShape Lifesciences® is America’s premier
weight loss and metabolic health-solutions company, offering an
integrated portfolio of proven products and services that manage
and treat obesity and metabolic disease. The FDA-approved Lap-Band®
System provides minimally invasive, long-term treatment of obesity
and is an alternative to more invasive surgical stapling procedures
such as the gastric bypass or sleeve gastrectomy. ReShapeCare™ is a
virtual weight-management program that supports lifestyle changes
for all weight loss patients led by board-certified health coaches
to help them keep the weight off over time. The recently launched
ReShape Marketplace™ is an online collection of quality wellness
products curated for all consumers to help them achieve their
health goals. The investigational Diabetes Bloc-Stim
Neuromodulation™ (DBSN™) system utilizes a proprietary vagus nerve
block and stimulation technology platform for the treatment of Type
2 diabetes and metabolic disorders. The Obalon® balloon technology
is a non-surgical, swallowable, gas-filled intra-gastric balloon
that is designed to provide long-lasting weight loss. For more
information, please visit www.reshapelifesciences.com.
Forward-Looking Safe Harbor
Statement This press release may contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Actual results could differ materially from
those discussed due to known and unknown risks, uncertainties, and
other factors. These forward-looking statements generally can be
identified by the use of words such as "expect," "plan,"
"anticipate," "could," "may," "intend," "will," "continue,"
"future," other words of similar meaning and the use of future
dates. Forward-looking statements in this press release include
statements that the DBSN™ device, with further studies, may hold
significant promise to treat T2DM and our efforts to potentially
bring this novel therapeutic to market . These and additional risks
and uncertainties are described more fully in the company's filings
with the Securities and Exchange Commission, including those
factors identified as "risk factors" in our most recent Annual
Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q.
We are providing this information as of the date of this press
release and do not undertake any obligation to update any
forward-looking statements contained in this document as a result
of new information, future events or otherwise, except as required
by law.
CONTACTSReShape Lifesciences Investor
Contact:Thomas StankovichChief Financial
Officer949-276-6042ir@ReShapeLifesci.com
Investor Relations Contact:Rx
Communications GroupMichael
Miller(917)-633-6086mmiller@rxir.com
ReShape Lifesciences (NASDAQ:RSLS)
Historical Stock Chart
From Apr 2024 to May 2024
ReShape Lifesciences (NASDAQ:RSLS)
Historical Stock Chart
From May 2023 to May 2024